Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07023848 | PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors | enrolling by invitation | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07023861 | The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies | enrolling by invitation | Early Phase 1 | 20 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 |
| clinicaltrials |
| NCT05320757 | Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients | completed | Early Phase 1 | 20 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03392181 | PET/MRI for the Staging of Newly Diagnosed Prostate Cancer | active not recruiting | Early Phase 1 | 48 | Northwestern UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03987217 | Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients | completed | Early Phase 1 | 73 | University of UtahOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06959966 | Effects of Oligo-fucoidan on Leiomyoma Patients | completed | Early Phase 1 | 18 | Taipei Medical UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery | withdrawn | Early Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03661437 | Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy | completed | Early Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03196180 | Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia | completed | Early Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2025 | clinicaltrials |
| NCT03768349 | PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer | completed | Early Phase 1 | 250 | Mayo ClinicOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06887673 | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds | not yet recruiting | Early Phase 1 | 56 | University of South FloridaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02420977 | Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer | completed | Early Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06864572 | [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer | enrolling by invitation | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients(TOASTIT) | terminated | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05110495 | IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy(WINGMEN) | completed | Early Phase 1 | 27 | University of OxfordOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06359821 | Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer | completed | Early Phase 1 | 4 | Sichuan UniversityOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | terminated | Early Phase 1 | 2 | Floor Backes, MDOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06825455 | Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Peking UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03473730 | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | completed | Early Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06756334 | Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis | recruiting | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 3, 2025 | clinicaltrials |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | withdrawn | Early Phase 1 | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT02042430 | Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Early Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03232164 | PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer | completed | Early Phase 1 | 126 | University of Wisconsin, MadisonOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | terminated | Early Phase 1 | 95 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Nov 22, 2024 | clinicaltrials |
| NCT03378297 | IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC(IMPACT) | completed | Early Phase 1 | 26 | Haukeland University HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05707182 | 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study | withdrawn | Early Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06612580 | 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study | recruiting | Early Phase 1 | 10 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05518812 | Carboprost (Hemabate) for Fibroid Resection | completed | Early Phase 1 | 19 | Northwestern UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02952469 | Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC | completed | Early Phase 1 | 22 | University of IowaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT05549024 | 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients | recruiting | Early Phase 1 | 90 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06428708 | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma | unknown | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06462495 | Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | unknown | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06462508 | Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | unknown | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 17, 2024 | clinicaltrials |
| NCT03275857 | Cisplatin in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 12 | University of RochesterOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06437496 | 68Ga-AAZTA-093 PET/CT: First-in-human Study | unknown | Early Phase 1 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02113657 | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | completed | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03358563 | Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer | completed | Early Phase 1 | 30 | University of Wisconsin, MadisonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04726033 | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)(CUPID) | completed | Early Phase 1 | 14 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT02728830 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | completed | Early Phase 1 | 39 | AA SecordOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05773703 | Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer | completed | Early Phase 1 | 23 | Ratio Therapeutics, Inc.INDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | terminated | Early Phase 1 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05725070 | Phase 0/1 Study of 212Pb-NG001 in mCRPC | completed | Early Phase 1 | 3 | ARTBIO Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05567679 | A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer | withdrawn | Early Phase 1 | 0 | Edwin Posadas, MDOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06050239 | Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer | unknown | Early Phase 1 | 10 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04831541 | 68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer | unknown | Early Phase 1 | 600 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01253213 | BR55 in Prostate Cancer: an Exploratory Clinical Trial | completed | Early Phase 1 | 26 | Bracco Diagnostics, IncINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2025source: clinicaltrials